NCT03939923View on ClinicalTrials.gov

Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions
SurgeryCoronary Artery Disease
Interventions
DRUG

Rocuronium

Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.

DRUG

Neostigmine

Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)

DRUG

Glycopyrrolate

Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)

DRUG

Sugammadex

Reversal with Sugammadex (2mg/kg)

Trial Locations (1)

26506

WVU Medicine, Morgantown

All Listed Sponsors
lead

West Virginia University

OTHER

NCT03939923 - Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery | Biotech Hunter | Biotech Hunter